Manhattan BioSolutions, Inc.

Manhattan BioSolutions, Inc. ("MABS"), an emerging biotechnology company developing new classes of precision biologics that harness natural host defense mechanisms, today announced that its RNA-targeting therapeutic, MABS-139, will be evaluated in...

Manhattan BioSolutions, Inc. (MABS), an emerging biotech company developing new classes of precision biologics for the treatment of advanced cancers, and the Institute of Chemical Biology & Drug Discovery (ICB&DD) at Stony Brook University, led...

Manhattan BioSolutions, Inc. ("Manhattan Bio"), an emerging biotechnology company developing new classes of precision biologics for the treatment of advanced cancers, today announced a collaborative poster presentation at the American Association for...

Manhattan BioSolutions, Inc. (Manhattan Bio or MABS), an emerging biotech company developing innovative precision biologics, today announced its selection as an awardee of the Science in the City QuickFire Challenge launched by Johnson & Johnson...